BioCentury | Nov 8, 2010
Finance

Blue skies for pain plays

...Pharmaceuticals Inc. filed to raise up to $86.3 million in an IPO. The company (formerly Blue Acquisition Corp....
BioCentury | Apr 30, 2007
Clinical News

DepoCyt cytarabine regulatory update

...March, SkyePharma plc (LSE:SKP; SKYE, London, U.K.) sold its injectable business, which included DepoCyt, to Blue Acquisition...
...also is approved in Europe and is provided under a named patient basis in Canada. Blue Acquisition Corp....
BioCentury | Apr 2, 2007
Finance

Ebb & Flow

...payments that are contingent on sales. SKP also sold its San Diego injectable unit to Blue Acquisition...
...in cash, with the potential for an additional $62 million in milestones hinging on sales. Blue Acquisition...
BioCentury | Apr 2, 2007
Company News

SkyePharma, Blue Acquisition, Paul Capital Partners deal

...previously announced sale of its injectable business, including DepoDur morphine to treat post-surgical pain, to Blue Acquisition...
...in cash and up to $62 million in milestones, plus royalties (see BioCentury, Jan. 15). Blue Acquisition...
...million in payments linked to future sales of DepoDur. SkyePharma plc (LSE:SKP; SKYE), London, U.K. Blue Acquisition Corp....
BioCentury | Mar 27, 2007
Company News

SkyePharma sells injectable unit, raises L14.8 million

...delivery company SkyePharma (LSE:SKP; SKYE) completed the previously announced sale of its injectable business to Blue Acquisition Corp....
...of 61.2 million shares at 24.5p per share. Credit Suisse acted as sole placement agent. Blue Acquisition...
BioCentury | Jan 15, 2007
Company News

SkyePharma, Blue Acquisition deal

...SKP agreed to sell its injectable business, SkyePharma Inc., to Blue Acquisition Corp. for $20 million in cash...
...enter Phase III trials this year. It also includes drug delivery platforms DepoFoam and Biospheres. Blue Acquisition...
...MPM Capital L.P., OrbiMed Advisors LLC and Sanderling Ventures. SkyePharma plc (LSE:SKP; SKYE), London, U.K. Blue Acquisition Corp....
BioCentury | Jan 10, 2007
Company News

SkyePharma to sell injectable unit, raise L14.8 million

...Drug delivery company SkyePharma (LSE:SKP; SKYE) agreed to sell its injectable business to Blue Acquisition Corp. for $20...
...61.2 million shares at 24.5p per share. Credit Suisse will act as sole placement agent. Blue Acquisition...
Items per page:
1 - 7 of 7
BioCentury | Nov 8, 2010
Finance

Blue skies for pain plays

...Pharmaceuticals Inc. filed to raise up to $86.3 million in an IPO. The company (formerly Blue Acquisition Corp....
BioCentury | Apr 30, 2007
Clinical News

DepoCyt cytarabine regulatory update

...March, SkyePharma plc (LSE:SKP; SKYE, London, U.K.) sold its injectable business, which included DepoCyt, to Blue Acquisition...
...also is approved in Europe and is provided under a named patient basis in Canada. Blue Acquisition Corp....
BioCentury | Apr 2, 2007
Finance

Ebb & Flow

...payments that are contingent on sales. SKP also sold its San Diego injectable unit to Blue Acquisition...
...in cash, with the potential for an additional $62 million in milestones hinging on sales. Blue Acquisition...
BioCentury | Apr 2, 2007
Company News

SkyePharma, Blue Acquisition, Paul Capital Partners deal

...previously announced sale of its injectable business, including DepoDur morphine to treat post-surgical pain, to Blue Acquisition...
...in cash and up to $62 million in milestones, plus royalties (see BioCentury, Jan. 15). Blue Acquisition...
...million in payments linked to future sales of DepoDur. SkyePharma plc (LSE:SKP; SKYE), London, U.K. Blue Acquisition Corp....
BioCentury | Mar 27, 2007
Company News

SkyePharma sells injectable unit, raises L14.8 million

...delivery company SkyePharma (LSE:SKP; SKYE) completed the previously announced sale of its injectable business to Blue Acquisition Corp....
...of 61.2 million shares at 24.5p per share. Credit Suisse acted as sole placement agent. Blue Acquisition...
BioCentury | Jan 15, 2007
Company News

SkyePharma, Blue Acquisition deal

...SKP agreed to sell its injectable business, SkyePharma Inc., to Blue Acquisition Corp. for $20 million in cash...
...enter Phase III trials this year. It also includes drug delivery platforms DepoFoam and Biospheres. Blue Acquisition...
...MPM Capital L.P., OrbiMed Advisors LLC and Sanderling Ventures. SkyePharma plc (LSE:SKP; SKYE), London, U.K. Blue Acquisition Corp....
BioCentury | Jan 10, 2007
Company News

SkyePharma to sell injectable unit, raise L14.8 million

...Drug delivery company SkyePharma (LSE:SKP; SKYE) agreed to sell its injectable business to Blue Acquisition Corp. for $20...
...61.2 million shares at 24.5p per share. Credit Suisse will act as sole placement agent. Blue Acquisition...
Items per page:
1 - 7 of 7